The current ESC/EAS guideline recommends lowering LDL-C <1.4 mmol/L for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in very high-risk patients. However, despite favourable LDL-C control, atherosclerosis still continues to progress, which eventually causes cardiovascular events. Ther...
Y. Kataoka, S. Nicholls, S. Kitahara et al.· European Heart Journal· 0 citations
An increased risk of cardiovascular events was observed in patients with CAD who exhibited ANGPTL3> 363.4 ng/mL, and the findings suggest circulating ANGPTL3 as a potential therapeutic target to further mitigate subsequent cardiovascular events’ risks in patients with CAD.
S. Fujita, Y. Kataoka, N. Kuyama et al.· European Heart Journal· 0 citations
Early intensive lipid-lowering therapy is recommended after acute coronary syndrome (ACS), and current guidelines recommend assessing attainment of lipid-lowering targets within 4–6 weeks; however, the prognostic significance of achieving a more than 50% reduction in low-density lipoprotein cholesterol (LDL-C) sh...
K. Murai, K. Mitsui, T. Iwai et al.· European Heart Journal· 0 citations
Coronary atheroma in patients with PolyVD was resistant to lowering LDL-C <55 mg/dL, and lipoprotein(a) may be a potential therapeutic target to delipidate coronary atheroma.
A. Katasako-Yabumoto, Yu Kataoka, S. Nicholls et al.· Journal of the American Hear...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.